ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ABEO / financials
CAMP (26) AMRN (32) IFRX (54) EVMN (31) ⌘ Pro Terminal →

Abeona Therapeutics Inc. (ABEO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.25 -2.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.22

Abeona Therapeutics Inc. (ABEO) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $248.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABEO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Abeona Therapeutics Inc. (NASDAQ: ABEO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $4.25 (-2.30% 1D, market cap $248.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABEO ranks #946 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABEO compare to CAMP and AMRN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABEO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 73.7%, and ROIC of -35.0%. By comparison, CAMP (CAMP4 Therapeutics Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M) and AMRN (Amarin Corporation plc) posts a E grade (32/100 RQD, P/E N/A, ROIC -12.2%, cap $249.9M). Among the 5-stock peer group, ABEO leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABEO?
▼

Per ABEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318306), Abeona Therapeutics Inc. generated $5.8M in revenue (-96.8% YoY), -$71.2M in net income, and -$84.3M in free cash flow against $219.6M in total assets and $7.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.22 (-0.60%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (4)Whales (3)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.8% Base Target
$8 Bull$4 Base$3 Bear
📬 FREE ABEO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABEO)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY ABEO SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (35% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$4.52+1.8% Next Q
Q2 (-2Q)
28
Grade E$4.60-3.3% Next Q
Q3 (-1Q)
26
Grade E$4.45-4.5% Next Q
Current
23
Grade E$4.25-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABEO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABEO currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.18) and Max Pain ($4.46) forces dealer call-delta covering toward $8.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABEO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABEO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ABEO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$5.8MGross Profit $4.3M (73.7%)Cost of Sales $1.5MOp Profit $0 (0%)OpEx (R&D/SG&A) $4.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $3.5M
FY24
Rev $179.8M
FY25
Rev $5.8M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$5.8M73.7%-80%-$71.2M-$84.3M-45%
FY 2024$179.8M73.7%-35.7%$63.7M-$58.5M-45%
FY 2023$3.5M73.7%-80%$54.2M-$37.0M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABEO)

  • ✓Walkthrough of ABEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.57%📐 HORIZONTAL RANGE
2026-11-03O $4.56H $4.56L $4.25C $4.25VOL 783.4K
RES: $9.06SUP: $3.89SMA50: $5.18SMA200: $5.48
$7.89$6.90$5.92$4.93$3.94RES $9.06SUP $3.89$4.252026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABEO Butterfly Map → + Track ABEO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -96.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABEO)

Health Care Rank #946 of 1015 ⚔️ CAMP vs ABEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABEO vs. CAMP, AMRN, IFRX, EVMN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Abeona Therapeutics Inc. (ABEO) ranks #946 by composite RQD confidence (23/100, grade E) and #542 by equity capitalization ($248.8M). Within this direct 5-issuer industry benchmark cohort, ABEO leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. IFRX currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ABEO at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABEO ACTIVE
Abeona Therapeutics Inc.
E 23/100 — 73.7% -35.0% -2.30% $248.8M Benchmark Subject
CAMP
CAMP4 Therapeutics Corporation
E 26/100 — — -35.0% -4.67% $248.5M /camp-vs-abeo →
AMRN
Amarin Corporation plc
E 32/100 — 56.6% -12.2% +0.17% $249.9M /amrn-vs-abeo →
IFRX
InflaRx N.V.
D+ 54/100 — — — +6.33% $244.6M /ifrx-vs-abeo →
EVMN
Evommune Inc.
E 31/100 — — -35.0% -10.70% $244.2M /evmn-vs-abeo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318306 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abeona Therapeutics Inc. (ABEO) reported GAAP revenue of $5.8M (-96.8% vs. FY2024 revenue of $179.8M , and +66.3% cumulative change since FY2023) , GAAP net income of -$71.2M, operating cash flow of -$76.3M, and free cash flow of -$84.3M (-44.2% YoY). On the balance sheet, ABEO closed FY2025 with $219.6M in total assets against $7.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.8M -$71.2M -$76.3M -$84.3M $219.6M $7.8M
FY2024 (FY) 2024-12-31 $179.8M $63.7M -$56.0M -$58.5M $108.9M $13.0M
FY2023 (FY) 2023-12-31 $3.5M $54.2M -$37.0M -$37.0M — —

3. ABEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Abeona Therapeutics Inc. (NASDAQ: ABEO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $4.25 (-2.30% 1D, market cap $248.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ABEO ranks #946 in composite RQD confidence.

How does ABEO compare to CAMP and AMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABEO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 73.7%, and ROIC of -35.0%. By comparison, CAMP (CAMP4 Therapeutics Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M) and AMRN (Amarin Corporation plc) posts a E grade (32/100 RQD, P/E N/A, ROIC -12.2%, cap $249.9M). Among the 5-stock peer group, ABEO leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABEO?

Per ABEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318306), Abeona Therapeutics Inc. generated $5.8M in revenue (-96.8% YoY), -$71.2M in net income, and -$84.3M in free cash flow against $219.6M in total assets and $7.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABEO trading relative to its 50-day, 200-day, and 52-week technical levels?

ABEO last traded at $4.25 (-2.30% on volume of 1,011,847 shares), positioning the stock -17.95% below its 50-day simple moving average ($5.18) and -22.45% below its 200-day simple moving average ($5.48). Across its 52-week range of $4.00 to $7.65, ABEO sits at the 6.8% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($3.85 to $4.65).

Direct Sub-Reports: ABEO RQD Cockpit ABEO 12M Forecast ABEO Earnings & Move ABEO Dividends & DRIP ABEO Insiders & 13F ABEO Whale Options ABEO Profit Sankey ABEO News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

ABEO — Abeona Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Abeona Therapeutics Inc. (ABEO) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.25 (-2.30% 1D, market capitalization $248.8M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 73.7%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of 0.05x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Abeona Therapeutics Inc. (ABEO) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $248.8M, gross margin of 73.7%, operating margin of -60.0%, and return on invested capital (ROIC) of -35.0%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Abeona Therapeutics Inc. (ABEO) reported $5.8M in annual revenue (up from $179.8M in FY2024, -96.8% YoY) and -$71.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.5M revenue, $54.2M net income) through FY2025, ABEO scaled operating cash flow to -$76.3M and free cash flow to -$84.3M, backed by $219.6M in total assets against $7.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.00 – $7.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ABEO carries a macro regime beta of 1.00 and gross margin of 73.7%.

  • Key Question #1: Can ABEO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $5.8M and free cash flow of -$84.3M, how will capital allocation balance growth reinvestment against $7.8M in total debt?
  • Key Question #3: How sensitive is ABEO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABEO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abeona Therapeutics Inc. (ABEO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABEO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABEO Bull vs. Bear Conversation Board — What's Your Call at $4.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABEO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABEO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.18 (+19.1%)
📌 Pinned Debate

Debt/Equity of 0.05 and $78.4M in FY 2025 cash give the company a low-leverage balance sheet despite losses.

Don't sleep on ABEO's setup in Health Care. Debt/Equity of 0.05 and $78.4M in FY 2025 cash give the company a low-leverage balance sheet despite losses.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (23/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $4.35 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $3.48 (-20.0%)
Spot @ $4.35

ROIC of -35%, FCF yield of 0%, and an Altman Z of 0.2 signal the cash engine is not self-funding and carries distress risk.

Fading this rally in ABEO at $4.35. ROIC of -35%, FCF yield of 0%, and an Altman Z of 0.2 signal the cash engine is not self-funding and carries distress risk.. With a beta of 1.0 and the stock sitting at $4.35 (52-wk range $4.00–$7.65), the easy multiple expansion is already priced in.

LIVE TAPE